Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Novo Nordisk Archives
Print | Email | Share | Comments (0)

Thanks, But No Thanks-Novartis and Novo Discontinue Their Relationship in Drug's Development


Jan 1, 2002
On October 29, 2001, Novo Nordisk announced it will continue the development of its dual-acting insulin sensitizer without the involvement of Novartis Pharma. The insulin sensitizer, called NN622, is currently in development for the treatment of type 2 diabetes.

Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk, said: "Our development program for NN622 continues unaffected by Novartis's decision. Initiation of the phase 3 program is progressing according to schedule√Č Results from our phase 2 studies confirmed that the profile of NN622 meets the therapeutic objectives we had set. In terms of commercialization of the product in North America we will now be considering various alternatives."

Novartis, on the other hand, is saying that NN622 failed phase 2 criteria, according to Reuters. Thomas Ebeling, head of the Swiss group's drugs division, declined to say whether the problem was related to the product's safety profile.

"We have an ambitious product profile which includes efficacy and safety, and our assessment after having looked at the phase 2 data simply was that this product does not meet that target profile."

Reuters reports that Novartis's decision to pull out of plans to commercialize NN622 came less than a week after GlaxoSmithKline stopped development of a similar drug because of adverse side effects.



-D. Trecroci

Categories: Diabetes, Diabetes, General, Insulin, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.